The Latest Breaking News on Pharma

Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."

AMD expands its private bug bounty program to the general public, allowing anyone who signs up for an Intigriti account to submit bugs and get paid.

Texas has tapped more than $45 million in federal funds to get the overdose-reversing drug into the hands of law enforcement, members of the public. But the program has been plagued by supply issues, delays and lack of communication.

In their first major strike in a decade, pharmacists across France stopped work on Thursday to draw attention to drug shortages, forced closures and potential restrictions on online sales. They also want higher pay.

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

Amid growing demand for specialty drugs and increasing adoption of emerging technology in pharmaceutical manufacturing, the pharma industry is witnessing steady expansion. Therefore, quality pharmaceutical stocks Zoetis (ZTS), Viatris (VTRS), MEI Pharma (MEIP), and Amphastar Pharmaceuticals (AMPH) could be ideal additions to your watchlist. Keep reading….

Given growing healthcare spending, supportive government policies, and technological innovation, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider buying quality biotech stocks Harmony Biosciences (HRMY), Esperion Therapeutics (ESPR), and Entrada Therapeutics (TRDA), which are trading at a discount. Read on….

Social media and messaging apps such as Facebook, Instagram, Snapchat and Messenger are increasingly used to buy and sell drugs in many countries. New Zealand is no exception.

Several stocks across different industry groups including health care, software and retail are clearing buy points with their relative strength at new highs.

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade

The growth will be fuelled by 20 new drugs that are set to launch this decade